David Scadden sold $9,256 of AGIO
director at AGIOS PHARMACEUTICALS, INC.. 200 shares at an average of $46.28, traded Dec 11, 2024, filed Dec 13, 2024.
Score components
- +15RoleDirector
- 0Trade size$9k at market
- 0Share of holdings soldSold 1.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.7%, 3m -20.6%, 6m -12.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001439222-24-000146, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2024 | MOption exercise Common stock10b5-1 | +200 | $18.09 | $3,618 | 15,683 | Dec 13, 2024 |
| Dec 11, 2024 | SOpen-market sale Common stock10b5-1 | -200 | $46.28 | $9,256 | 15,483 | Dec 13, 2024 |
| Dec 11, 2024 | MOption exercise Stock options (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 29,107 | Dec 13, 2024 |
Related signals
Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $914k 30,000 shares | -35% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $151k 4,007 shares | -5% | |
| 30Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $662k 19,068 shares | -10% | |
| 10Weak | AGIOS PHARMACEUTICALS, INC. | Krishnan Viswanadhan Chief Corp Dev & Strategy | $103k 2,959 shares | -22% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Tsveta Milanova Chief Commercial Officer | $113k 3,262 shares | -7% | |
| 12Weak | AGIOS PHARMACEUTICALS, INC. | Cecilia Jones Chief Financial Officer | $109k 3,141 shares | -5% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $102k 2,940 shares | -4% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | James William Burns Chief Legal Officer | $114k 3,280 shares | -6% | |
| 14Weak | AGIOS PHARMACEUTICALS, INC. | Krishnan Viswanadhan Chief Corp Dev & Strategy | $82k 2,959 shares | -37% | |
| 61Notable | AGIOS PHARMACEUTICALS, INC. | Theodore James Washburn Jr. Principal Accounting Officer | $152k 5,272 shares | -86% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.